Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
New Head To Head Data(1) Show Efficacy Of Treatment With Lumigan For Intraocular Pressure - Key Risk Factor For Glaucoma

New Head To Head Data(1) Show Efficacy Of Treatment With Lumigan For Intraocular Pressure - Key Risk Factor For Glaucoma

Dec 11 2007 | comment(s)

WESTPORT, Ireland, December 11 /PRNewswire/ --

- FOR HEALTHCARE PROFESSIONAL MEDIA ONLY

Treatment with LUMIGAN(R) (bimatoprost) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost combined with timolol (LTFC), according to a study published in Ophthalmology this month.

These are the results of a randomised, double-blind, study which set out to compare the effects of LUMIGAN(R) and LTFC over a 24-hour period on IOP, the leading risk factor for glaucoma.(2) Glaucoma is the second leading cause of blindness globally(3).

SurgiLance Safety Lancets Now Registered With French Needlestick Safety Agency

SurgiLance Safety Lancets Now Registered With French Needlestick Safety Agency

Dec 11 2007 | comment(s)

PARIS, December 11 /PRNewswire/ --

MediPurpose, a top provider of medical safety devices, announced today that its SurgiLance safety lancet has been validated by the Safety Medical Device Commission of GERES, the French advocacy organization for needlestick safety.

With the recent approval, SurgiLance safety lancet will be featured on the GERES website (www.geres.org) under the heading "Guide des Materiels de Protection." GERES provides a list of approved safety products for medical staff, helping to assure the safety of healthcare providers.

ClipSyndicate Signs Video Content Deal With The Press Association For International Distribution

ClipSyndicate Signs Video Content Deal With The Press Association For International Distribution

Dec 11 2007 | comment(s)

NEW YORK, December 11 /PRNewswire/ --

- The News Agency's First Syndication Agreement with US Online Video Distribution Platform

Quintiles Appoints John Goodacre As General Counsel

Quintiles Appoints John Goodacre As General Counsel

Dec 11 2007 | comment(s)

RESEARCH TRIANGLE PARK, North Carolina, December 11 /PRNewswire/ --

Quintiles Transnational Corp. today announced the appointment of John Goodacre as Executive Vice President and General Counsel.

Previously Senior Vice President, Global Risk Management and Quality Assurance, Goodacre joined Quintiles in 1998 as Vice President, European Legal Affairs.

Endeavors And Vector Networks Join Forces

Endeavors And Vector Networks Join Forces

Dec 11 2007 | comment(s)

IRVINE, California and LONDON, December 11 /PRNewswire/ --

- New Americas Partner Displaces AppStream with Endeavors AppExpress

Endeavors Technologies, the pioneer in application streaming and virtualization technology, and its parent company, Tadpole Technology plc, today announced a partner agreement with Vector Networks, a leading provider of desktop management software for the enterprise. Vector is integrating Endeavors' application streaming and virtualization software as a key component of its IT Asset Management Solution.

PNH Patients With Lower Levels Of Hemolysis, Mild Anemia And Minimal Transfusion Support Have Significant Disease Burden; Soliri

PNH Patients With Lower Levels Of Hemolysis, Mild Anemia And Minimal Transfusion Support Have Significant Disease Burden; Soliri

Dec 11 2007 | comment(s)

CHESHIRE, Connecticut, December 11 /PRNewswire/ --

- Data Presented at the American Society of Hematology (ASH) Annual Meeting

- Publication Number: 840

Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe disease, according to data from an ongoing open-label clinical study presented today at the 49th Annual Meeting of the American Society of Hematology Meeting in Atlanta.